Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Neoplasms × olaparib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 34 Breast Neoplasms 20 Neoplasms 12 Prostatic Neoplasms 10 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Pancreatic Neoplasms 6 Carcinoma, Ovarian Epithelial 5 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Metastatic Castration-resistant Prostate Cancer 4 Fanconi Anemia, Complementation Group D1 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Solid Tumors 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 2 Carcinoma 2 Advanced Solid Tumours 2 Advanced Solid Tumor 2 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

Azacitidine 11 venetoclax 7 AP 1903 reagent 6 Itraconazole 5 fludarabine 4 fedratinib 4 belinostat 4 Rituximab 4 Cytarabine 4 Bortezomib 4 ARQ531 4 pomalidomide 3 ibrutinib 3 daratumumab 3 cc-486 3 angiotensin I (1-7) 3 Lenalidomide 3 Imatinib Mesylate 3 Dexamethasone 3 Daunorubicin 3 Cyclophosphamide 3 tosedostat 2 tazemetostat 2 tanespimycin 2 talquetamab 2 tafasitamab 2 romidepsin 2 pembrolizumab 2 ixazomib 2 glasdegib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03486873 2026-03-16

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡